
SECTION 1: FWA, ETHICAL PRINCIPLES AND REGULATIONS, HUMAN RESEARCH PROTECTION PROGRAM

1.1 FEDERALWIDE ASSURANCE (FWA) FOR THE PROTECTION OF HUMAN SUBJECTS ................................................................. 3
   A. Institutional Review Board (IRB) Information: ........................................... 3
   B. Terms of the Federal Wide Assurance for the Protection of Human Subjects (FWA)....... 3
      i. Human Subjects Research is Guided by a Statement of Principles ....................... 3
      ii. Applicability ............................................................................................. 3
      iii. Compliance with Laws, Regulations, Policies, and Guidelines............................... 3
         a. U.S. Institutions ...................................................................................... 3
         b. Non-U.S. Institutions .............................................................................. 4
         c. U.S. and non-U.S. Institutions ................................................................... 5
      iv. Written Procedures .................................................................................... 5
      v. Institutional Support for the IRB(s) ............................................................... 6
      vi. Reliance on an External IRB ..................................................................... 6
      vii. Renewal or Update of the Assurance ....................................................... 6

1.2 OVERVIEW OF ETHICAL PRINCIPLES AND REGULATIONS GOVERNING THE PROTECTION OF HUMAN SUBJECTS ......................................................... 6
   A. Ethical Principles and Regulations Governing the Protection of Human Subjects ...... 7
      i. Belmont Report .......................................................................................... 7
      ii. DHHS Regulations (Title 45 Code of Federal Regulations) .................................. 8
      iii. FDA Regulations (Title 21 Code of Federal Regulations) .................................. 8
   B. Definitions and Jurisdiction of the IRB ........................................................... 9
      i. Research ..................................................................................................... 9
      ii. Clinical Investigation (FDA) ...................................................................... 10
      iii. Human Subject ........................................................................................ 10
      iv. Intervention (OHRP) ............................................................................... 10
      v. Interaction (OHRP) .................................................................................. 10
      vi. Test Article (FDA) .................................................................................. 10
      vii. Private Information (OHRP) .................................................................. 11
      viii. Identifiable Private Information .............................................................. 11
      ix. Identifiable Biospecimen .......................................................................... 11
      x. Clinical Trial ............................................................................................ 11
   C. Determining Whether an Activity Constitutes Human Subjects Research .......... 11
   D. Research Collaborations and Engagement ................................................... 11
   E. Research Projects in which an Employee of Our Institution is a Consultant .......... 13
   F. Investigator’s Engaged in Research Conducted at Non-Institutional Sites .......... 13
G. Quality Assurance and Quality Improvement Activities .......................................................... 14
1.3 HUMAN RESEARCH PROTECTION PROGRAM (HRPP) .................................................. 14
A. HRPP Quality Improvement: .................................................................................................. 14
   i. IRB Membership, Training, and Submission Metrics Quality Improvement Activities 14
   ii. Routine Monitoring of the HRPP ...................................................................................... 15
   iii. Needs Assessments ........................................................................................................... 15
   iv. HRPP Educational, Training, and Outreach programs ...................................................... 15
1.1 FEDERALWIDE ASSURANCE (FWA) FOR THE PROTECTION OF HUMAN SUBJECTS

The Ann & Robert H. Lurie Children’s Hospital of Chicago, the Stanley Manne Children’s Research Institute, and the Children’s Hospital of Chicago Medical Center – hereafter collectively referred to as the “Institution” – accept responsibility for protecting the rights and welfare of human subjects participating in research governed by the Institution.

A. Institutional Review Board (IRB) Information:

- Federalwide Assurance: FWA 00001011
- IRB Organization (IORG) #: 0000368
- HHS Registration #: IRB00000624 and IRB00009723
- Federal EIN #36-2170833

B. Terms of the Federal Wide Assurance for the Protection of Human Subjects (FWA)

U. S. Department of Health and Human Services (DHHS)
Office for Human Research Protections (OHRP)

i. Human Subjects Research is Guided by a Statement of Principles

All of the Institution’s human subjects research activities, regardless of whether the research is subject to the U.S. Federal Policy for the Protection of Human Subjects (also known as the Common Rule), is be guided by a statement of principles governing the Institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects research conducted at or sponsored by the Institution. This statement of principles includes (a) the Institution’s Code of Conduct, the World Medical Association’s Declaration of Helsinki, and the statement of ethical principles outlined in the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the U.S. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Common Rule was updated in 2018 with a general compliance date to meet the new requirements of January 21, 2019.

ii. Applicability

These terms apply whenever the Institution becomes engaged in human subjects research conducted or supported whole or in part by any U.S. federal department or agency that has adopted the Common Rule, unless the research is otherwise exempt from the requirements of the Common Rule, or unless a U.S. federal department or agency conducting or supporting the research determines that the research shall be conducted under a separate assurance. Refer to OHRP Guidance on Engagement.

iii. Compliance with Laws, Regulations, Policies, and Guidelines

a. U.S. Institutions

When the Institution becomes engaged in research to which the FWA applies, the Institution and Institutional Review Boards (IRBs) upon which it relies for review of such research will comply with the Common Rule.
The reference in the U.S. Code of Federal Regulations is shown below for each U.S. federal department and agency that has adopted the Common Rule:

7 CFR part 1c – Department of Agriculture
10 CFR part 745 – Department of Energy
14 CFR part 1230 – National Aeronautics and Space Administration
15 CFR part 27 – Department of Commerce
16 CFR part 1028 – Consumer Product Safety Commission
22 CFR part 225 – Agency for International Development
24 CFR part 60 – Department of Housing and Urban Development
28 CFR part 46 – Department of Justice (*has not adopted the 2018 changes to the Common Rule)
32 CFR part 225 – Department of Defense
34 CFR part 97 – Department of Education
38 CFR part 16 – Department of Veterans Affairs
40 CFR part 26 – Environmental Protection Agency
45 CFR part 46, subpart A – Department of Health and Human Services
45 CFR part 46, subpart A – Central Intelligence Agency (by Executive Order 12333)
45 CFR part 46, subpart A – Department of Homeland Security (by federal statute)
49 CFR part 690 – National Science Foundation
49 CFR part 11 – Department of Transportation

b. Non-U.S. Institutions

When the Institution becomes engaged in research to which the FWA applies, the Institution and IRBs upon which it relies for review of such research at a minimum will comply with one or more of the following:

1. The Common Rule;

2. The U.S. Food and Drug Administration regulations at 21 CFR parts 50 and 56;

3. The current International Conference on Harmonization E-6 Guidelines for Good Clinical Practice;

4. The current Council for International Organizations of Medical Sciences International Ethical Guidelines for Biomedical Research Involving Human Subjects;

5. The current Canadian Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans;

6. The current Indian Council of Medical Research Ethical Guidelines for Biomedical Research on Human Subjects; or

7. Other standard(s) for the protection of human subjects recognized by U.S. federal departments and agencies that have adopted the U.S. Federal Policy for the Protection of Human Subjects.

If a U.S. federal department or agency head determines that the procedures prescribed by the Institution afford protections that are at least equivalent to those
provided by the Common Rule, the department or agency head may approve the substitution of the foreign procedures in lieu of the procedural requirements provided above, consistent with the requirements of section 101(h) of the Common Rule.

c. U.S. and non-U.S. Institutions

For any research to which the FWA applies, the Institution also will comply with any additional applicable human subjects regulations and policies of the U.S. federal department or agency which conducts or supports the research and any other applicable federal, state, local, or institutional laws, regulations, and policies. When the Institution is engaged in non-exempt human subjects research conducted or supported by HHS, the Institution will comply with the requirements of subparts B, C, D, and E of the HHS regulations at Title 45 Code of Federal Regulations part 46, when applicable, for research involving pregnant women, fetuses, and neonates; prisoners; and children, respectively.

Human subjects research conducted or supported by each U.S. federal department or agency listed above will be governed by the regulations as implemented by the respective department or agency. The head of the U.S. federal department or agency retains final judgment as to whether a particular activity conducted or supported by the respective department or agency is covered by the Common Rule. If the Institution needs guidance regarding implementation of the Common Rule and/or other applicable U.S. federal regulations, the Institution should contact appropriate officials at the U.S. federal department or agency conducting or supporting the research. For U.S. federally conducted or supported research covered by the FWA, the U.S. federal department or agency that conducts or supports the research retains final authority for determining whether the Institution complies with the Terms of Assurance. If HHS receives an allegation or indication of noncompliance related to research to which the FWA applies and that is conducted or supported solely by a U.S. federal department or agency other than HHS, HHS will refer the matter to the other U.S. federal department or agency for review and action as appropriate.

iv. Written Procedures

The Institution submitting the FWA has established written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, the head of any U.S. federal department or agency conducting or supporting the research (or designee), and OHRP of any:

a. unanticipated problems involving risks to subjects or others;
b. serious or continuing noncompliance with the applicable U.S. federal regulations or the requirements or determinations of the IRB(s); and
c. suspension or termination of IRB approval.

The Institution will ensure that the IRB(s) that reviews research to which the FWA applies has established written procedures for the following:

a. conducting IRB initial and continuing review (not less than once per year), of research, and reporting IRB findings to the investigator and the Institution;
b. determining which projects require review more often than annually and which projects need verification from sources other than the investigator that no material changes have occurred since the previous IRB review; and

c. ensuring prompt reporting to the IRB of proposed changes in a research activity, and for ensuring that such changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval, except when necessary to eliminate apparent immediate hazards to the subjects.

Upon request, the Institution will provide a copy of these written procedures to OHRP or any U.S. federal department or agency conducting or supporting research to which the FWA applies.

v. Institutional Support for the IRB(s)

The Institution will ensure that each IRB upon which it relies for review of research to which the FWA applies has meeting space and sufficient staff to support the IRB’s review and recordkeeping duties.

vi. Reliance on an External IRB

Whenever the Institution relies upon an IRB operated by another institution or organization for review of research to which the FWA applies, the Institution must ensure that this arrangement is documented by a written agreement between the Institution and the other institution or organization operating the IRB that outlines their relationship and includes a commitment that the IRB will adhere to the requirements of the Institution’s FWA. OHRP’s sample IRB Authorization Agreement may be used for such purpose, or the parties involved may develop their own agreement. This agreement must be kept on file at both institutions/organizations and made available upon request to OHRP or any U.S. federal department or agency conducting or supporting research to which the FWA applies.

vii. Renewal or Update of the Assurance

The Institution must renew its FWA every 5 years, even if no changes have occurred, in order to maintain an active FWA.

The Institution must update its FWA within 90 days after changes occur regarding the legal name of the Institution, the Human Protections Administrator, or the Signatory Official.

Any renewal or update that is submitted to, and accepted by, OHRP begins a new 5-year effective period.

Failure to renew or update an FWA appropriately may result in restriction, suspension, or termination of OHRP’s approval of the Institution’s FWA.

1.2 OVERVIEW OF ETHICAL PRINCIPLES AND REGULATIONS GOVERNING THE PROTECTION OF HUMAN SUBJECTS
A. Ethical Principles and Regulations Governing the Protection of Human Subjects

i. Belmont Report

The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research was established in 1974 with the passage of the National Research Act. The Commission met from 1974 to 1978 and published The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, on April 18, 1979. The Belmont Report identifies the basic ethical principles underlying the acceptable conduct of research involving human subjects. Those principles, respect for persons, beneficence, and justice, are now accepted as the three fundamental requirements for the ethical conduct of human subjects research and serve as the basis for regulations and guidelines pertaining to the protection of human subjects. The Institution’s investigators, research staff, IRB members, IRB staff, and in working with sponsors, follow the ethical principles of the Belmont Report for all human subjects research.

a. Autonomy and Respect for persons involves recognition of the personal dignity and autonomy of individuals and necessitates special protection for persons with diminished autonomy. The ethical principle of respect for persons requires that researchers disclose complete information about the nature of research to prospective subjects and obtain their informed consent prior to engaging them in research-related activities. In addition, it justifies additional protections for individuals who are vulnerable or of diminished capacity.

b. Beneficence necessitates the protection of persons from harm by maximizing anticipated benefits and minimizing possible risks of harm. It is in consideration of this ethical principle that the IRB is required to conduct a systematic assessment of risks and benefits associated with research. Adhering to the ethical principle of beneficence, the IRB may review the scientific merits of a research study to determine that the potential benefits and the likelihood of their occurrence outweigh the potential risks and the likelihood of their occurrence.

c. Justice requires that the benefits and burdens of research be distributed fairly among individuals and different classes of people. Accordingly, this principle directs the IRB to carefully consider the selection of research subjects. The IRB must judge whether some classes are being systematically selected simply because of their easy availability, their compromised position, or their manipulability, rather than for reasons directly related to the problem being studied. Furthermore, the principle of justice requires that researchers apply equal selection standards to all potential subjects. Accordingly, they should not offer potentially beneficial research only to individuals who will make the most convenient and manageable subjects; likewise, they should not limit the subject population to certain groups - such as racial minorities, the socio-economically disadvantaged, the very sick, or the institutionalized, when conducting risky research.

The Belmont Report also provides important guidance related to distinguishing medical practice from research. The Report defines the term ‘practice’ as “interventions that are designed solely to enhance the well-being of an individual patient or client and that
have a reasonable expectation of success.” The term ‘research,’ on the other hand, refers to “an activity designed to test a hypothesis, permit conclusions to be drawn, and thereby to develop or contribute to generalizable knowledge.” The Belmont Report explains that it is important for the distinction between practice and research to be clear to human subjects, particularly those who participate in research activities with the expectation of receiving some treatment for their illness or condition. The Belmont Report holds that this distinction is especially crucial in cases where a subject’s treating physician is also the researcher. In such a context, the subject may harbor a “therapeutic misconception,” believing that participation in the research must be the best option simply because the treating physician recommends it.

ii. DHHS Regulations (Title 45 Code of Federal Regulations)

The Institution holds a federal-wide assurance from OHRP and functions in full compliance with the applicable federal, state, and local laws. The DHHS regulations for the protection of human subjects in research were codified at the Code of Federal Regulations (CFR) Title 45 Part 46 (45 CFR 46) All research involving human subjects, which receives federal funding, must comply with the DHHS regulations. OHRP is the federal oversight entity within DHHS responsible for the administration of 45 CFR 46.

The DHHS regulations contain four Subparts that provide the foundation for the review and approval of all research conducted at the Institution regardless of funding.

a. Subpart A, Federal Policy for the Protection of Human Subjects (Basic DHHS Policy for Protection of Human Research Subjects), has been adopted by seventeen federal agencies that conduct, support, or otherwise regulate human subjects research in order to ensure uniformity of the human subjects protection system. Subpart A is also referred to as the “Common Rule.”

b. Subpart B of 45 CFR 46 regulates research involving pregnant women, human fetuses, and neonates.

c. Subpart C of 45 CFR 46 outlines additional protections for prisoners involved as subjects in research.

d. Subpart D of 45 CFR 46 describes additional regulations for children involved as subjects in research.

All research involving human subjects that is conducted by staff of the Institution on its premises or under its sponsorship, regardless of funding source, must be reviewed and approved by the IRB. This also applies to personnel who conduct research at other hospitals, institutions, or places external to the Institution. Individuals who are not affiliated with the Institution, but who are involved in research activities that involve the Institution’s patients must also follow these policies and procedures.

iii. FDA Regulations (Title 21 Code of Federal Regulations)

The provisions of the Food, Drug, and Cosmetic Act of 1938 provide authority to the Food and Drug Administration (FDA) to regulate clinical investigations, development, and approval of drugs, biologics, and devices. The FDA regulations for the protection of human subjects are contained in Title 21 of the Code of Federal Regulations Part 50 (21 CFR 50). The FDA regulations governing IRBs are contained in Title 21 of the
Code of Federal Regulations Part 56 (21 CFR 56). All research activities involving food, investigational new drugs, biologics, or medical devices, and approved drugs, biologics, or medical devices which are used off-label must comply with all applicable FDA regulations and Good Clinical Practice (GCP) standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials.

The Institution participates in clinical research that is under the jurisdiction of the FDA, and complies with the regulations under 21 CFR 50, (Informed Consent); 21 CFR 50 Subpart D, 21 (Children); 21 CFR 56 (IRB Regulations); 21 CFR 312 (Investigational New Drug Applications); 21 CFR 612, (Biological Products); and 21 CFR 812 (Investigational Device Exemptions).

B. Definitions and Jurisdiction of the IRB

The Institution defines human subject research as any activity that either represents research that involves human subjects as defined by OHRP regulations, or any activity that represents research/clinical investigation that involves human subjects as defined by FDA regulations.

At the Institution, all research involving human subjects must comply with institutional policies and applicable regulations. Additionally, the Institution complies with all applicable state laws and regulations regarding human subjects’ research. State law and regulations will supersede federal regulations when it imposes greater restrictions on research conduct (e.g., age of assent, age of consent, and surrogate decision-making, etc.). The Institution uses the following definitions from OHRP to determine what constitutes human subjects research. The proposal must involve both research and human subjects (as defined below) in order to be considered human subjects research.

Activities that meet the definition of human subjects research below are subject to review by the IRB. Included in the purview of the IRB is the review of all uses of human tissue/specimens, including autopsy material, as the IRB serves as the Privacy Board for research activities for the Institution.

i. Research

Both OHRP and the FDA define research as a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. OHRP has deemed the following activities not to be research [45 CFR 46.102(l)]:

(1) Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom the information is collected.

(2) Public health surveillance activities, including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority. Such activities are limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health
importance (including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products). Such activities include those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters).

(3) Collection and analysis of information, biospecimens, or records by or for a criminal justice agency for activities authorized by law or court order solely for criminal justice or criminal investigative purposes.

(4) Authorized operational activities (as determined by each agency) in support of intelligence, homeland security, defense, or other national security missions.

ii. Clinical Investigation (FDA)

Any experiment that involves a test article and one or more human subjects, and that either must meet the requirements for prior submission to the FDA or the results of which are intended to be later submitted to, or held for inspection by, the FDA as part of an application for a research or marketing permit [21 CFR 50.3(c)].

iii. Human Subject

FDA defines a human subject as an individual who is or becomes a subject in research, either as a recipient of the test article or as a control or an individual on whose specimen a device was used. A subject may be either a healthy human or a patient [21 CFR 50.3(e)].

OHRP defines human subject as a living individual about whom an investigator (whether professional or student) conducting research:

1) Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies or analyzes the information or biospecimens; or
2) Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.

iv. Intervention (OHRP)

Intervention includes both physical procedures by which information or biospecimens are gathered (e.g., venipuncture) and manipulation of the subject or the subject's environment that are performed for research purposes.

v. Interaction (OHRP)

Interaction includes communication or interpersonal contact between an investigator and subject.

vi. Test Article (FDA)

Refers to any drug (including a biological product for human use), medical device for human use, human food additive, color additive, electronic product, or any other article subject to FDA regulation [21 CFR 50.3(c) and 21 CFR 50.3(j)].
vii. Private Information (OHRP)

Information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information that has been provided for specific purposes by an individual and that the individual can reasonably expect will not be made public (e.g., a medical record).

viii. Identifiable Private Information

Identifiable private information is private information for which the identity of the subject is or may readily be ascertained by the investigator or associated with the information.

ix. Identifiable Biospecimen

An identifiable biospecimen is a biospecimen for which the identity of the subject is or may readily be ascertained by the investigator or associated with the biospecimen.

x. Clinical Trial

A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

C. Determining Whether an Activity Constitutes Human Subjects Research

The OHRP and FDA guidelines are used to determine if an activity is human subject research by applying the definitions outlined above.

i. Activities Subject to IRB Review

The Office of Research Integrity and Compliance (ORIC) offers guidance and direction on activities that may require IRB review. An activity requires IRB approval or determination of exempt status if the following criteria are met:

a. The proposed activity meets the definition of “research;”

b. The proposed activity will involve the collection of data or biospecimens from or about “human subjects;” and

c. Institutional involvement in the activity meets the criteria of “engagement” in research per OHRP guidance.

During consideration of inquiries regarding what may require IRB review, investigators are encouraged to contact ORIC staff for guidance. If required, investigators will be requested to submit an initial application via the electronic IRB system, with additional details regarding the proposed project for official determination.

Determinations may be made by the staff of ORIC following the regulatory definitions of “research” and “human subject” in addition to the OHRP letter on engagement of institutions in research. If necessary, an IRB Chair or Vice-Chair will participate in the review. In some cases, where the request is more involved, it may become necessary to consult further with federal oversight agencies. Final determinations will be communicated to the requestor via the electronic IRB system.

D. Research Collaborations and Engagement
The IRB is responsible for the oversight of all research involving human subjects (as defined by the regulations) that is conducted by members of the Institution’s workforce, which includes medical staff, research staff, or employees regardless of the location of the research or funding source. The Institution’s workforce is defined as those individuals who receive their paycheck from the Institution or one of its entities. Outside locations may need to apply for an assurance of compliance with OHRP if the location is engaged in the research and there is no IRB available at the site.

The IRB follows the definition of “collaboration” employed by NIH Office of Human Research Subjects, which states that collaboration exists if a researcher expects “something in return” as a result of having participated in a research activity. Collaborative activities may include the collection of specimens, visits to institutions to perform research activities or clinical work, exchange of information containing personal identifiers, preliminary data collection activities involving human subjects, substantive intellectual contributions to research techniques, protocol design, or interpretation of data, and under some circumstances, supplying important reagents, performing tests or analyzing data.

Before agreeing to participate in a research activity with an outside investigator, each Institutional investigator must first define the nature of the outside investigator’s role and determine whether their participation will constitute “engagement” in human subjects research. If the outside investigator is engaged in human subjects research (as outlined in the OHRP Guidance on Engagement of Institutions in Human Subjects Research), IRB approval (or certification of exemption from IRB review) from the “home” institution of the outside investigator must be obtained before the outside investigator may engage in any study activity. If an outside investigator will be engaged in research activity at our Institution, they must also be added to the study personnel list. Common collaborative activities that would require IRB approval (or certification of exemption from IRB review) include:

i. The institution receives an award through a grant, contract, or cooperative agreement directly from HHS for the non-exempt human subjects research (i.e. awardee institutions), even where all activities involving human subjects are carried out by employees or agents of another institution.

ii. The institution’s employees or agents intervene for research purposes with any human subjects of the research by performing invasive or noninvasive procedures.

iii. The institution’s employees or agents intervene for research purposes with any human subject of the research by manipulating the environment.

iv. The institution’s employees or agents interact for research purposes with any human subject of the research.

v. The institution’s employees or agents obtain the informed consent of human subjects for the research.

vi. The institution’s employees or agents obtain for research purposes identifiable private information or identifiable biological specimens from any source for the research. It is important to note that, in general, institutions whose employees or agents obtain identifiable private information or identifiable specimens for non-exempt human subjects’ research are considered engaged in the research, even if the institution’s employees or agents do not directly interact or intervene with human subjects. In
general, obtaining identifiable private information or identifiable specimens includes, but is not limited to:

a. observing or recording private behavior;

b. using, studying, or analyzing for research purposes identifiable private information or identifiable specimens provided by another institution; and

c. using, studying, or analyzing for research purposes identifiable private information or identifiable specimens already in the possession of the investigators.

In general, OHRP considers private information or specimens to be individually identifiable as defined in 45 CFR 46.102(f) when they can be linked to specific individuals by the investigator(s) either directly or indirectly through coding systems.

E. Research Projects in which an Employee of Our Institution is a Consultant

The Institution’s IRB review is required for any human subject research activity undertaken by an employee or agent of the Institution unless the employee or agent functions strictly as a consultant to the research team, holds no rights to the work (such as study design, data analysis, publication, co-authorship, etc.), and does not obtain, receive, or possess identifiable and private information about any research subject.

F. Investigator’s Engaged in Research Conducted at Non-Institutional Sites

When an Institutional employee or agent participates in a multicenter study, or a research project by conducting research-related procedures at non-Institution site, the project must be reviewed and approved by both the Institution’s IRB and the lead site’s IRB or the local IRB of the research site. Documentation of the lead site’s or local IRB approval for the conduct of research at the non-affiliated site must be maintained by the investigator.

More frequently, one IRB may opt to rely on the review of an external IRB. In this case, a Reliance Agreement, a formal written document that provides a mechanism for an institution engaged in research to delegate IRB review to an external IRB, is needed. Such an agreement may also be referred to as a Cooperative Agreement or IRB Authorization Agreement (IAA), is. Cooperative research projects are those projects covered by this policy that involve more than one institution. In the conduct of cooperative research projects, each institution is responsible for safeguarding the rights and welfare of human subjects. Agreements may cover reliance for a single study, categories of studies, or all human subjects research under an organization’s Federalwide Assurance (FWA). Such an agreement should clearly identify the IRB of record and the delineation of responsibilities of all parties to facilitate collaboration and trust. While permissible under 45 CFR 46.114 for an institution to rely on an IRB of another OHRP-approved institution for protocol review, the Institution’s IRB will ultimately determine whether it is in the best interests of the subjects to accept a determination by another IRB.

Under 21 CFR 56.114, institutions participating in multicenter studies may use joint review, rely on the review of another qualified IRB, or establish other arrangements to reduce duplicative efforts. For select multicenter trials, the Institution may choose to rely primarily on the review of a central or external IRB. If this is done, the Institution’s IRB will review the multicenter protocol and supporting documents, the meeting minutes from the central or external IRB, and ensure the informed consent documents meet the Institution’s requirements.
The IRB Chair and Institutional Official (IO) are consulted when ORIC receives requests for this type of arrangement. Investigators should contact the ORIC for questions regarding reliance agreements.

G. Quality Assurance and Quality Improvement Activities

It is important to recognize that some Quality Assurance (QA) or Quality Improvement (QI) activities conducted at the Institution may be classified as human subject research. Most QA and QI activities are assessments developed and initiated with the intent of assuring or improving the process, outcome, and/or efficiency of complex systems of health care. However, if the primary goal is to produce generalizable knowledge as defined in section B above, the activities are subject to the regulations governing the protection of human research subjects and require prior IRB review. Further guidance about requirements for QA/QI projects can be found in Section 7 Guidance on Quality Improvement and Assurance Projects of this manual. Investigators are also encouraged to contact ORIC staff for assistance in this area.

1.3 HUMAN RESEARCH PROTECTION PROGRAM (HRPP)

The Institution’s Human Research Protection Program (HRPP) includes all persons and departments of the Institution engaged in the planning, design, review, conduct, or administrative support of any research involving human subjects. The Institution’s HRPP is guided by the ethical principles outlined in this policy and is committed to the education of the research community and outreach to collaborating institutions.

A. HRPP Quality Improvement:

The Institution will routinely evaluate the resources needed for the HRPP, including but not limited to:

- Space
- Personnel
- IRB membership, education and training, and submission metrics
- Legal counsel
- Financial conflict of interest review and management
- HRPP routine monitoring and auditing programs (e.g. Post-Approval Monitoring Program)
- HRPP educational, training, and outreach programs

i. IRB Membership, Training, and Submission Metrics Quality Improvement Activities

- Review of IRB Membership

  ORIC will routinely evaluate IRB membership and qualifications to ensure that composition is in compliance with federal regulations. IRB Metrics

  ORIC tracks key IRB metrics (i.e., time from complete submission to approval for new studies submitted for all review types) and evaluates for ongoing process improvement. The HRPP is committed to maintaining IRB approval times to be in the top 50th percentile as compared to the Association for the Accreditation of Human Research Protection Programs (AAHRPP) annual HRPP metric reports. If approval times are lagging, investigation into causes will be initiated by ORIC administration and solutions to address delays will be designed and implemented.
• IRB Member education and training

The HRPP is committed to ensuring the IRB members and Chair(s) are equipped with the necessary knowledge and tools to conduct robust and ethical reviews of human subjects research. The IRB members are routinely provided continuing education in the form of: presentations at convened meetings, discussion of issues related to human subjects research, relevant articles, guidance documents, and opportunities for attendance at local/virtual educational events.

ii. Routine Monitoring of the HRPP

The Institution conducts routine post-approval monitoring to assess compliance of the HRPP with organizational policies and procedures, applicable laws, regulations, codes and guidance. Objectives include, but are not limited to: improving compliance in the proper conduct of the informed consent process, monitoring the maintenance of regulatory documentation, and reviewing the documentation of inclusion/exclusion criteria. Random monitoring is conducted each month to review the specified objective for assessing compliance. Feedback and recommendations for improvement are directly provided to investigators and research staff. When recurring errors are identified, policies are revised for clarification. In addition, “global” e-mails to investigators and research staff are sent out weekly to highlight such issues and educate the entire research community. If necessary and appropriate, it may also become a topic for a research town hall meeting or other applicable means of targeted education.

Annual trends are monitored to evaluate the effectiveness of the post-approval monitoring process and related recommendations, education, etc. Additionally, data from routine monitoring will combined with patterns and trends identified during for-cause audits or investigations so that education and training of the research enterprise is disseminated accordingly.

iii. Needs Assessments

The continuing education and training needs of the HRPP investigators, and research staff are an integral part of the Institution’s research mission. Under the leadership of the ORIC Education staff, the HRPP conducts a periodic needs assessment survey to identify gaps in education, training and competency related to the conduct of human subjects research. The results of each needs assessment are shared with HRPP Leadership which will then assist with developing the goals for training and education. Any deficiencies will be specifically addressed with the support of leadership in that identified area.

iv. HRPP Educational, Training, and Outreach programs

ORIC Education staff provide ongoing education related to the protections of human subjects research and training related to conducting research according to good clinical practices/best practices and ensuring operational compliance with federal regulations, laws, and IRB determinations. The program is assessed annually with goals and outcomes defined from completed HRPP needs assessments. Mixed-methods approaches that follows principles of adult education forms the foundation of the
education and training programming. Metrics and tracking of outcomes are shared routinely with research/HRPP leadership and the IRB.

In addition, ORIC conducts activities designed to enhance and facilitate the communication between the HRPP and the Institution’s research enterprise. This includes having ORIC staff membership on research committees throughout the Institution, conducting regular needs assessments as stated above, promoting regular office hours for consultation with ORIC staff, and communicating HRPP changes and improvement activities via global emails. The HRPP also performs outreach activities that seeks the understanding of human research by participants, prospective participants, or their communities. These outreach activities are evaluated on a periodic basis for improvement.